Chronic obstructive pulmonary disease (COPD)

The global burden of chronic obstructive pulmonary disease (COPD) continues to escalate, ranking as one of the leading causes of morbidity and mortality worldwide. This progressive respiratory condition is primarily characterized by persistent airflow limitation, chronic inflammation, and debilitating symptoms such as dyspnea and frequent exacerbations. Research has advanced our understanding of disease mechanisms, highlighting the roles of genetic susceptibility, oxidative stress, and environmental exposures beyond smoking. Early detection through advanced imaging and biomarkers is gaining traction as a crucial step in improving outcomes. Clinicians now rely on multidimensional approaches that combine pharmacologic interventions with pulmonary rehabilitation, oxygen therapy, and surgical options for selected patients. Personalized medicine strategies, such as targeting phenotypes and endotypes, are offering promising directions for more effective management. The integration of digital health technologies—including remote monitoring and AI-driven predictive models—further enhances patient follow-up and treatment adherence. With ongoing developments in novel bronchodilators, anti-inflammatory agents, and regenerative therapies, chronic obstructive pulmonary disease (COPD) care is entering a transformative era that emphasizes not just symptom control but also slowing disease progression and improving long-term quality of life.